利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

78 条记录 (耗时 0.027 秒)

    Synthetic composition for microbiota modulation
    2.
    发明授权
    Synthetic composition for microbiota modulation 有权

    公开(公告)号：US11696921B2

    公开(公告)日：2023-07-11

    申请号：US17001118

    申请日：2020-08-24

    申请人： GLYCOM A/S

    发明人： Louise Kristine Vigsnæs ,  Bruce McConnell

    IPC分类号： A61K31/702 ,  A61P3/04 ,  A61P3/10 ,  A61P1/00 ,  A61K9/00

    CPC分类号： A61K31/702 ,  A61K9/0053 ,  A61P1/00 ,  A61P3/04 ,  A61P3/10

    摘要： A human milk oligosaccharide (HMO) or a synthetic composition comprising said HMO, for use in increasing the abundance, particularly the relative abundance, of a Bifidobacterium of the B. adolescentis phylogenic group in the microbiota in the gastro-intestinal tract of a human, preferably a non-infant human. The HMO(s) and/or synthetic composition is useful in; increasing particularly the relative abundance of B. adolescentis and/or B. pseudocatenulatum; for treating or preventing in said non-infant human with type 2 diabetes and/or obesity; an enteropathogenic infection; impaired gut barrier function and/or; an inflammation related to gastro¬intestinal condition, preferably irritable bowel disease (IBD) or irritable bowel syndrome (IBS); as a nutritional composition. The HMO is a fucosylated neutral HMO, a non-fucosylated neutral HMO, or a mixture of a fucosylated and a non-fucosylated neutral HMO. The HMOs comprises 2′-fucosyllactose (preferred), 2′-fucosyllactose (preferred), 3-fucosyllactose, difucosyllactose (preferred), lacto-N-fucopentaose, fucosyl-lacto-N-hexaose, fucosyl-para-lacto-N-hexaose, lacto-N-tetraose (preferred), lacto-N-neotetraose (preferred), lacto-N-hexaose, lacto-N-neohexaose, para-lacto-N-hexaose and para-lacto-N-neohexaose.

    Mixture of HMOs
    5.
    发明授权
    Mixture of HMOs 有权

    公开(公告)号：US11432578B2

    公开(公告)日：2022-09-06

    申请号：US16062598

    申请日：2016-12-15

    申请人： GLYCOM A/S

    发明人： Bruce McConnell ,  Louise Kristine Vignæs

    IPC分类号： A23L33/00 ,  A61K31/702 ,  A23L33/135 ,  A61P31/12 ,  A61P31/04 ,  A23L33/12 ,  A23L33/19 ,  A23L33/195

    摘要： A synthetic mixture of human milk oligosaccharides (HMOs) consisting essentially of lacto-N-neotetraose (LNnT), lacto-N-tetraose (LNT), 2′-fucosyllactose (2′FL), 3′-O-sialyllactose (3′-SL), 6′-O-sialyllactose (6′-SL) either difucosyllactose (DFL) or 3-fucosyllactose (3-FL), preferably DFL, and optionally lactose. Said synthetic composition is useful for: treating or preventing viral and/or bacterial infection in a non-infant human; modulating the microbiota of a non-infant human; and/or improving the cognitive function of a non-infant human and as a pharmaceutical or nutritional composition.

    MIXTURE OF HMOS FOR TREATING AUTOIMMUNE DISEASES
    6.
    发明申请
    MIXTURE OF HMOS FOR TREATING AUTOIMMUNE DISEASES 有权

    公开(公告)号：US20210213038A1

    公开(公告)日：2021-07-15

    申请号：US17059942

    申请日：2019-05-31

    申请人： Glycom A/S

    发明人： Louise Kristine Vigsnæs ,  Bruce McConnell ,  Kristine Rothaus Christensen

    IPC分类号： A61K31/702

    摘要： The invention relates to a method, compounds and compositions for the secondary prevention, treatment or dietary management of symptomatic and asymptomatic non-intestinal autoimmune diseases in a non-infant human including Sjogren's syndrome and type 1 diabetes. Said method, compounds and compositions for the secondary prevention, treatment or dietary management include human milk oligosaccharide (HMO), preferably mixtures of human milk oligosaccharides selected from the group of 2′-FL, LNnT, LNT, DFL, and 6′-SL.

    Mixtures of HMOs
    8.
    发明授权
    Mixtures of HMOs 有权

    公开(公告)号：US10946032B2

    公开(公告)日：2021-03-16

    申请号：US16435949

    申请日：2019-06-10

    申请人： Glycom A/S

    发明人： Elise Champion ,  Bruce McConnell ,  Gyula Dekany

    IPC分类号： A61K31/702 ,  C07H5/06 ,  C12P19/26 ,  A61K31/715 ,  C12P19/18 ,  A61K31/7016

    摘要： The invention relates to a mixture of human milk oligosaccharides that consists essentially of: a) a component A which is 3-FL or DFL, a component B which is LNT, LNnT, LNFP-I or 2′-FL, a component C, which is LNFP-II when component B is LNT, or LNFP-III when component B is LNnT, or LNDFH-I when component B is LNFP-I, or DFL when component B is 2′-FL, and a component D, which is lactose when component A is 3-FL, or 2′-FL when component A is DFL, with the proviso that if component B is 2′-FL, then component A is 3-FL; or consists essentially of: b) 3-FL, a component E which is LNT, LNnT or LNFP-I, and a component F, which is LNFP-II when component E is LNT, or LNFP-III when component E is LNnT, or LNDFH-I when component E is LNFP-I, and to processes for producing them and their uses.